Cyramza ® (ramucirumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Cyramza Summary of Product Characteristics (SmPC)

Cyramza® (ramucirumab): Renal Impairment

Clinical data suggest that no dose adjustments are required in patients with mild, moderate or severe renal impairment.

Detailed Information

There have been no formal studies with ramucirumab in patients with renal impairment. Clinical data suggest that no dose adjustments are required in patients with mild, moderate or severe renal impairment. No dose reductions are recommended.1

Based on the results of the PopPK analysis, ramucirumab exposure was similar in patients with mild renal impairment (calculated CrCl ≥60 to <90 mL/min), moderate renal impairment (CrCl ≥30 to <60 mL/min), or severe renal impairment (CrCl <30 mL/min) as compared to patients with normal renal function (CrCl ≥90 mL/min).1

References

1. Cyramza [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

CrCL = creatinine clearance

PopPK = population pharmacokinetic 

Date of Last Review: August 15, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question